JP2007505139A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505139A5 JP2007505139A5 JP2006526349A JP2006526349A JP2007505139A5 JP 2007505139 A5 JP2007505139 A5 JP 2007505139A5 JP 2006526349 A JP2006526349 A JP 2006526349A JP 2006526349 A JP2006526349 A JP 2006526349A JP 2007505139 A5 JP2007505139 A5 JP 2007505139A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- analgesic
- opioid agonist
- patient
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 62
- 230000000202 analgesic effect Effects 0.000 claims 26
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 12
- 239000002756 mu opiate receptor agonist Substances 0.000 claims 11
- 239000003402 opiate agonist Substances 0.000 claims 11
- 229960005181 morphine Drugs 0.000 claims 9
- 208000023504 respiratory system disease Diseases 0.000 claims 9
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 8
- 229960002085 oxycodone Drugs 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 201000002859 sleep apnea Diseases 0.000 claims 4
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 3
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 3
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 3
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 claims 3
- 229960002428 fentanyl Drugs 0.000 claims 3
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 3
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 3
- 229960001410 hydromorphone Drugs 0.000 claims 3
- 229960003406 levorphanol Drugs 0.000 claims 3
- 229960001797 methadone Drugs 0.000 claims 3
- 229960005118 oxymorphone Drugs 0.000 claims 3
- 229960003394 remifentanil Drugs 0.000 claims 3
- 208000003417 Central Sleep Apnea Diseases 0.000 claims 2
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 2
- 229960001391 alfentanil Drugs 0.000 claims 2
- 208000020020 complex sleep apnea Diseases 0.000 claims 2
- 201000006646 mixed sleep apnea Diseases 0.000 claims 2
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 2
- 239000000014 opioid analgesic Substances 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 201000004813 Bronchopneumonia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 201000008197 Laryngitis Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000009243 chronic laryngitis Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 claims 1
- -1 safentanil Chemical compound 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 1
- 229960004739 sufentanil Drugs 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/661,458 US20050053659A1 (en) | 2003-09-10 | 2003-09-10 | Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
| US10/661,458 | 2003-09-10 | ||
| PCT/US2004/029731 WO2005025621A1 (en) | 2003-09-10 | 2004-09-10 | Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007505139A JP2007505139A (ja) | 2007-03-08 |
| JP2007505139A5 true JP2007505139A5 (enExample) | 2007-10-18 |
| JP5712452B2 JP5712452B2 (ja) | 2015-05-07 |
Family
ID=34227071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526349A Expired - Fee Related JP5712452B2 (ja) | 2003-09-10 | 2004-09-10 | 診断された呼吸疾患を有する患者もしくは診断未確定の呼吸疾患を有する患者におけるオピオイド鎮痛薬の投与に関連する危険性を減少するための方法および組成 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20050053659A1 (enExample) |
| EP (2) | EP2311496A1 (enExample) |
| JP (1) | JP5712452B2 (enExample) |
| WO (1) | WO2005025621A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2412409T3 (es) | 1997-12-22 | 2013-07-11 | Euro-Celtique S.A. | Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo |
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| US20030065002A1 (en) | 2001-05-11 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
| ES2320748T5 (es) | 2002-04-05 | 2017-02-20 | Euro-Celtique S.A. | Matriz para la liberación sostenida, invariable e independiente de compuestos activos |
| US20050053659A1 (en) * | 2003-09-10 | 2005-03-10 | Pace Gary W. | Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
| EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
| EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
| WO2007047576A1 (en) * | 2005-10-14 | 2007-04-26 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatments for sleep disorders |
| DE102007021549A1 (de) * | 2007-05-08 | 2008-11-13 | Novosis Ag | Transdermales therapeutisches System enthaltend mindestens zwei Opioide |
| US20090291975A1 (en) * | 2008-05-20 | 2009-11-26 | Warren Stern | Dual opioid pain therapy |
| UY32487A (es) | 2009-03-10 | 2010-06-30 | Euro Celtique Sa | Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona |
| WO2011011528A1 (en) * | 2009-07-23 | 2011-01-27 | Musc Foundation For Research Development | Isopropylphenidate for the treatment of attention-deficit/hyperactivity disorder and fatigue-related disorders and conditions |
| US20110046173A1 (en) * | 2009-08-24 | 2011-02-24 | Warren Charles Stern | Combination analgesic opioid pain therapy |
| US7923453B1 (en) | 2009-10-14 | 2011-04-12 | QRxPharma Ltd. | Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia |
| US8222267B2 (en) | 2009-10-14 | 2012-07-17 | QRxPharma Ltd. | Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia |
| US8012990B2 (en) * | 2009-10-14 | 2011-09-06 | QRxPharma Ltd. | Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia |
| CA2811285A1 (en) | 2010-09-14 | 2012-03-22 | QRxPharma Ltd. | Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia |
| US20120283283A1 (en) * | 2011-05-05 | 2012-11-08 | Stern Warren C | Methods for detecting enhanced risk of opioid-induced hypoxia in a patient |
| AU2012262061A1 (en) * | 2011-05-31 | 2013-05-09 | QRxPharma Ltd. | Compositions for sequential administration of opioid receptor agonists |
| UA116567C2 (uk) | 2013-07-23 | 2018-04-10 | Євро-Селтік С.А. | Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації |
| JP7369687B2 (ja) * | 2017-07-20 | 2023-10-26 | スーチョウ ランシンダタイ ファーマシューティクス エルティーディー シーオー． | 乱用防止長期作用型徐放性オピオイドプロドラッグ |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| HU208633B (en) * | 1991-02-04 | 1993-12-28 | Alkaloida Vegyeszeti Gyar | Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression |
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| GB9423542D0 (en) | 1994-11-22 | 1995-01-11 | Marples Brian A | Pharmaceutical compounds |
| AUPN603895A0 (en) * | 1995-10-19 | 1995-11-09 | University Of Queensland, The | Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids |
| US20050053656A1 (en) * | 2003-09-05 | 2005-03-10 | Ping Jeffrey H. | Compositions and methods for treating pain |
| US20050053659A1 (en) * | 2003-09-10 | 2005-03-10 | Pace Gary W. | Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
| CA2550023C (en) * | 2003-12-16 | 2011-04-12 | Cnsbio Pty Ltd | Treatment of neuropathic pain |
| US20090291975A1 (en) * | 2008-05-20 | 2009-11-26 | Warren Stern | Dual opioid pain therapy |
-
2003
- 2003-09-10 US US10/661,458 patent/US20050053659A1/en not_active Abandoned
-
2004
- 2004-09-10 EP EP10075496A patent/EP2311496A1/en not_active Withdrawn
- 2004-09-10 WO PCT/US2004/029731 patent/WO2005025621A1/en not_active Ceased
- 2004-09-10 EP EP04783810A patent/EP1667723A1/en not_active Withdrawn
- 2004-09-10 JP JP2006526349A patent/JP5712452B2/ja not_active Expired - Fee Related
-
2006
- 2006-10-06 US US11/544,187 patent/US8182837B2/en not_active Expired - Fee Related
-
2012
- 2012-04-11 US US13/444,073 patent/US20120316189A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007505139A5 (enExample) | ||
| EP1718336B1 (en) | Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases | |
| CN109689058B (zh) | 治疗和预防睡眠障碍 | |
| JP2010518122A5 (enExample) | ||
| JP2019534315A5 (enExample) | ||
| TNSN04147A1 (en) | Formoterol superfine formulation | |
| JP5208473B2 (ja) | アゼラスチンと抗コリン薬を含有する医薬組成物 | |
| JP5712452B2 (ja) | 診断された呼吸疾患を有する患者もしくは診断未確定の呼吸疾患を有する患者におけるオピオイド鎮痛薬の投与に関連する危険性を減少するための方法および組成 | |
| EP3538189A1 (en) | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions | |
| JP2010520185A5 (enExample) | ||
| AU2017379247A1 (en) | Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| CA3047426A1 (en) | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| WO2006065722A2 (en) | Compositions and methods for pulmonary conditions | |
| Islam et al. | Improved treatment of nicotine addiction and emerging pulmonary drug delivery | |
| HK1250015A1 (zh) | 镇咳药组合物和方法 | |
| JP2012516288A (ja) | 薬物乱用抑制剤、方法および組成物 | |
| US20120101076A1 (en) | Carbonate derivatives for the treatment of cough | |
| JP5091474B2 (ja) | フドステインと抗コリン薬を含有する医薬組成物 | |
| JP2017526719A5 (enExample) | ||
| JP2009508965A5 (enExample) | ||
| TW201118084A (en) | The use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders | |
| Jabalameli et al. | Comparison of intranasal versus intravenous pethidine for pain relief after cesarean section | |
| JP2015533131A (ja) | 咳を治療するためのベータ２−アドレナリン受容体作動薬 | |
| WO2008062453B1 (en) | Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form | |
| Machado et al. | Opioid analgesic choices based on pharmacokinetics |